LEISHMANIASIS DRUG

AEterna Laboratories reported recently the results of a phase III trial evaluating its drug Impavido (miltefosine) for the treatment of cutaneous leishmaniasis, showing that patients taking Impavido had a 220-percent better cure rate compared with those in a placebo group.

Related Videos
Related Content

Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

5 Perspectives on Laser Treatment in Dermatology

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Adel Haque, MD, Provides His Best Advice for New Dermatologists

March 28th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

5 Perspectives on Laser Treatment in Dermatology

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Adel Haque, MD, Provides His Best Advice for New Dermatologists

March 28th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

5 Perspectives on Laser Treatment in Dermatology

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Adel Haque, MD, Provides His Best Advice for New Dermatologists

March 28th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023
© 2023 MJH Life Sciences

All rights reserved.